The pharmaceutical company is implementing a leadership succession plan that includes board retirements, committee changes and governance continuity measures.

Ben Kruger’s elevation to chair forms the centrepiece of an extensive boardroom realignment. Image: Simon Dawson/Bloomberg

Aspen Pharmacare has initiated a structural overhaul of its governance leadership, positioning veteran banking executive Ben Kruger to take over as board chair. This is part of a sweeping succession pipeline that marks the departure of some of the multinational’s longest-serving directors.

The JSE-listed pharmaceutical giant confirmed the upcoming leadership transition in a compliance disclosure issued on Thursday. Kruger, the former co-CEO of Standard Bank Group who joined the Aspen board in 2019, will officially succeed outgoing chair Kuseni Dlamini at the conclusion of the company’s annual general meeting in December 2026.

Kruger’s elevation to chair forms the centrepiece of an extensive boardroom realignment. Having previously served as Aspen’s lead independent director and head of its audit and risk committee, Kruger will step down from the audit committee to assume the chair, while immediately joining the remuneration and nomination committee. The group indicated that a further announcement regarding a new lead independent director will follow in due course.

Read:
Aspen completes Apac exit with bigger-than-expected R27bn cash windfall
Africa CDC and top local drugmaker Aspen in vaccine supply talks

The leadership handover is part of a broader exit of legacy capital architects at the firm:

• The chair’s exit: Outgoing chair Kuseni Dlamini will step down entirely as an independent non-executive director in December, concluding a 14-year tenure on the board and over a decade as chair since his appointment in 2015.
• Retirement of a founding director: Non-executive director Chris Mortimer has signalled his retirement, opting not to stand for re-election. Mortimer’s exit brings to a close a 27-year tenure, having served on the board since 1999, spanning nearly the entirety of Aspen’s post-listing corporate history.
• Tenure extensions for continuity: To insulate the group from an abrupt loss of institutional memory, the board has extended the tenure of independent non-executive director Yvonne Muthien. Although Muthien reaches the company’s mandatory retirement age of 70 in September 2026, the board determined it was in the group’s “best interests” to retain her services for an additional year to maintain operational continuity.

The board extended high praise to its outgoing leadership, paying particular tribute to the historical legal and strategic frameworks established during the group’s formative years:

“The board wishes to express its sincere appreciation for Mr Mortimer’s outstanding contribution to Aspen, and in particular for the trusted legal counsel, wisdom and guidance he has provided to the group from its inception.”

Read: Local insulin production could reshape diabetes care across Africa

Acknowledging Dlamini’s leadership through a decade of global manufacturing and commercial expansion, the board added: “The board extends its sincere appreciation to Mr Dlamini for his exemplary leadership, steadfast commitment and significant contribution to Aspen over the years.”

To reinforce its statutory oversight during this transition period, Aspen also announced the immediate appointment of independent non-executive director Themba Mkhwanazi to its social and ethics committee. Management noted that Mkhwanazi’s “extensive experience in stakeholder engagement and sustainability” is expected to directly support the committee’s ongoing governance mandates as the new board takes shape under Kruger’s leadership.

Read: Stephen Saad on building Aspen and leading through pressure